Project ALS has selected Medidata’s biomarker discovery solution for its research projects, aiming to improve understanding of the ALS disease process and develop new therapeutic strategies.
Domainex is set to support Lunac’s discovery project for anticoagulant therapies with reduced bleeding risk, following the developer’s novel target validation.
Aiming to facilitate and accelerate discovery of biologics, Aridis’ Apex platform can also discover antibodies against viruses ‘within one day of a pandemic’.
Leveraging Eurofins’ pharmacology, in-vitro models and ADME capabilities, PharmaResources aims to accelerate drug discovery for its clients in small molecule drug R&D.
BioIVT taps into the advantages of hepatic cells for toxicology evaluations and screening studies, securing exclusive distribution agreement with upcyte.
Almirall enters drug discovery agreement with WuXi Biologics, gaining access to the WuXiBody platform to develop antibodies for the treatment of dermatological diseases.
Servier is set to support two research projects led by UCL to better understand the immune system’s collapse following infections from immune-inflammatory diseases.